Navigation Links
ChemDiv and Achaogen Enter Into a Discovery Collaboration
Date:1/29/2008

SAN DIEGO, Jan. 29 /PRNewswire/ -- ChemDiv, Inc., a leading chemistry-driven global contract research organization, has announced today that it has entered into a discovery collaboration with Achaogen, Inc., South San Francisco, CA. Applying its expertise in medicinal and synthetic chemistry, ChemDiv will support Achaogen in identifying and developing novel antibacterial compounds. Financial terms of the collaboration were not disclosed.

"We look forward to collaborating with Achaogen on this exciting project where ChemDiv's strong medicinal chemistry expertise and integrated drug discovery capabilities will provide our partner with the tools for successful research operations and help them achieve rapid progress in this area," said Alex Khvat, Sr. Director of Chemistry at ChemDiv, Inc.

"We are pleased to be working with ChemDiv on this important medicinal chemistry effort to optimize SOS pathway inhibitors discovered by Achaogen," said Dr. Heinz Moser, Achaogen's Senior Vice President for Chemistry. "These inhibitors could prove to be powerful new tools in the battle against antimicrobial resistance."

About ChemDiv, Inc.:

ChemDiv, Inc. (Chemical Diversity) is a global chemistry-driven contract research organization delivering discovery opportunities and services for life science partners. ChemDiv is merging industrial and academic efforts to bring new approaches to the treatment of life-threatening diseases. http://www.chemdiv.com

About Achaogen, Inc.:

Achaogen (a-KAY-oh-jen) is addressing the widespread emergence of bacterial resistance through the discovery and development of small molecule anti-infectives. Achaogen focuses on both known classes of antibiotics, as well as wholly novel classes of new drugs that will act through validated but as yet unexploited bacterial targets. For more information about Achaogen please contact John Hollway, Vice President, Business Development at 650-266-1120 or bd@achaogen.com, or visit http://www.achaogen.com.


'/>"/>
SOURCE ChemDiv, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
2. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
3. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
4. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
5. Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1
6. UniCare Unveils Community Resource Center in Topeka to Serve Medicaid Enrollees
7. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
8. Neogen Acquires Kane Enterprises
9. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
10. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
11. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... ... Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery, today announced ... for the further advancement of the company’s 3-month olanzapine product ( DLP-119 ). The ... therapeutic levels of olanzapine for a period of 3 months., “We are honored and ...
(Date:2/24/2017)... , Feb. 24, 2017 Symic Bio, ... developing a new category of therapeutics, announced today the ... SB-030 in peripheral artery disease. The trial will evaluate ... single-use therapeutic, in the reduction of restenosis following angioplasty. ... critical development milestone for SB-030," said Nathan Bachtell ...
(Date:2/24/2017)... Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading ... financial results for the fourth quarter and fiscal year of ... Total sales in the fourth quarter of ... 13.6% in USD terms to $77.6 million from $68.3 million ... profit increased by 13.3% to $46.8 million from $41.3 million ...
(Date:2/23/2017)... 2017 ... share data, unaudited)Three Months Ended December 31,Twelve Months Ended ... $           ... 89026%Aldurazyme Net Product Revenue 3539(10)%9498(4)%Kuvan ... Product Revenue  756025%297303(2)%Vimizim Net Product ...
Breaking Biology Technology:
(Date:2/7/2017)... , February 7, 2017 Ipsidy ... Solutions Corporation [OTC: IDGS], ("Ipsidy" or the "Company") a ... transaction processing services, is pleased to announce the following ... Effective January 31, 2017, Philip D. ... Directors, CEO and President.  An experienced payment industry professional ...
(Date:2/2/2017)... NEW YORK , Feb. 2, 2017  EyeLock ... has released a new white paper " What You ... The problem of ensuring user authenticity is a ... protect the authentication of users. However, traditional authentication schemes ... Biometric authentication offers an elegant ...
(Date:1/26/2017)... CITY , Jan. 26, 2017  Crossmatch, a ... unveiled a new solution aimed at combatting fraud, waste ... solution was introduced at the Action on Disaster Relief ... key meeting point for UN agencies and foreign assistance ... Fraud, waste and abuse are a largely unacknowledged ...
Breaking Biology News(10 mins):